Birdwatch Archive

Birdwatch Note Rating

2024-04-01 11:12:48 UTC - HELPFUL

Rated by Participant: 9F90484213C0914B6C118E46DB39F2CCF11E0A783A5232C7C924517CC9E5E92A
Participant Details

Original Note:

The rational reason for the price of Ozempik is to recover the $2 billion the company put into R&D to create the drug. https://t.co/u7A2EX9Kdk This spending drives drug innovation that ultimately benefits patients around the globe. Price caps in other countries limit innovation. https://healthpolicy.usc.edu/research/global-burden-of-medical-innovation/

All Note Details

Original Tweet

All Information

  • noteId - 1774641491010331092
  • participantId -
  • raterParticipantId - 9F90484213C0914B6C118E46DB39F2CCF11E0A783A5232C7C924517CC9E5E92A
  • createdAtMillis - 1711969968915
  • version - 2
  • agree - 0
  • disagree - 0
  • helpful - 0
  • notHelpful - 0
  • helpfulnessLevel - HELPFUL
  • helpfulOther - 0
  • helpfulInformative - 0
  • helpfulClear - 1
  • helpfulEmpathetic - 0
  • helpfulGoodSources - 1
  • helpfulUniqueContext - 0
  • helpfulAddressesClaim - 1
  • helpfulImportantContext - 1
  • helpfulUnbiasedLanguage - 1
  • notHelpfulOther - 0
  • notHelpfulIncorrect - 0
  • notHelpfulSourcesMissingOrUnreliable - 0
  • notHelpfulOpinionSpeculationOrBias - 0
  • notHelpfulMissingKeyPoints - 0
  • notHelpfulOutdated - 0
  • notHelpfulHardToUnderstand - 0
  • notHelpfulArgumentativeOrBiased - 0
  • notHelpfulOffTopic - 0
  • notHelpfulSpamHarassmentOrAbuse - 0
  • notHelpfulIrrelevantSources - 0
  • notHelpfulOpinionSpeculation - 0
  • notHelpfulNoteNotNeeded - 0
  • ratingsId - 17746414910103310929F90484213C0914B6C118E46DB39F2CCF11E0A783A5232C7C924517CC9E5E92A